Cancer nanomedicine: a review of recent success in drug delivery

Tran, Stephanie; DeGiovanni, Peter-Joseph; Piel, Brandon; Rai, Prakash

doi:10.1186/s40169-017-0175-0

Clinical and Translational Medicine

Table 2 Nanomedicines in clinical trials

From: Cancer nanomedicine: a review of recent success in drug delivery

Year	Name	Type of nano-particle	Active drug	Phase of trial	Size (nm)	Type of cancer	References
2017	NU-0129	Gold	Gold and siRNAs	I	*	Glioblastoma multiforme	[89, 90]
2017	MM-398	Liposome	Irinotecan	I, II, III	80–140	Small cell lung cancer, metastatic pancreatic adenocarcinoma, pediatric solid tumors	[70, 88, 91, 92]
2016*	Genexol-PM	Polymer	Paclitaxel	I/II	< 50	Gynecologic cancer, hepatocellular carcinoma, advanced breast cancer, non-small cell lung cancer	[93,94,95,96]
2016	CRLX101	Polymer	Camptothecin	I/II	30–40	Ovarian, rectal, renal, fallopian tube, lung (small cell and non-small cell) primary peritoneal, stomach, gastroesophageal, and esophageal cancers	[71, 72, 89, 97,98,99,100,101, 127]
2016	AuroLase	Silica-Gold	Gold	I	150	Prostate, head and neck, lung	[73, 102, 103]
2016	Vincristine sulfate liposome injection	Liposome	Vincristine	I/II	~ 100	Kaposiform hemangioendotheloma, Kasabach–Merritt Syndrome, tufted angioma, rhabdomyosarcoma, recurrent adult acute myeloid leukemia, lymphoblastic leukemia***, multiple lymphomas (non-hodgkin, follicular, mantle-cell, small-cell, and B-cell [Margional Zone]), Waldenstrom macroglobulinemia	[87, 104,105,106,107,108]
2016	Anti-EGFR immuno-liposome	Liposome	Doxorubicin	II	130–200	Breast cancer	[74, 109, 110]
2015	Mitoxantrone HCl liposome injection (plm60-s)	Liposome	Mitoxantrone	II	60	Breast cancer, diffuse large B-cell lymphoma, non-Hodgkin’s lymphoma, and peripheral T/NK lymphomas	[75, 111,112,113,114]
2014	CPX-351	Liposome		I	*	Acute myeloid leukemia	[115]
2014	LipoCURC	Liposome	Curcumin	I/II	*	Advanced cancer with failed standard of care therapy	[116]
2014	SGT-53	Liposome	Plasmid containing normal human wild type p53 DNA	I/II	*	Glioblastoma, neoplasm, metastatic pancreatic cancer	[117,118,119,120]
2013	LiPlaCis	Liposome	Cisplatin	I/II	*	Advanced or refractory solid tumours, metastatic breast cancer	[121, 122]
2012	PROMITIL	Liposome	Mitomycin-C	I	~ 90	Solid tumors	[123, 124]
2011	Abraxane	Protein-drug conjugate	Paclitaxel	II	~ 130	Breast cancer**	[125]

* Information not provided
** All patients are over the age of 65; breast cancers include estrogen receptor negative/positive, male breast cancer, Her2-negative/positive breast cancer, progesterone receptor positive/negative breast cancer, and several others
*** Patients were between age 1–21

Back to article page